Schiff and Osborne are developing laboratory models that will help them understand the mechanisms of resistance, thus allowing them to identify new treatments or new combinations that can prevent or reverse drug resistance. Research area: To identify key molecules responsible for breast cancer treatment resistance and to test new treatments that will improve outcomes.
Impact: While effective treatments for estrogen receptor ER -positive and HER2-positive breast cancers are available, many tumors are or become resistant to these therapies. Schiff and Osborne are conducting laboratory and clinical studies to understand resistance to endocrine and anti-HER2 therapy and develop new treatment strategies to overcome it. Schiff and Osborne have identified genetic aberrations in key proteins that alter the activity of ER and other transcription factors as a common mechanism of drug resistance and metastasis.
Understanding the consequences of these genetic events and how to therapeutically target them—using their experimental models—will pave the way for new clinical strategies to overcome resistance and improve patient outcome. They also plan to investigate known resistance mechanisms, identify new drivers of resistance to endocrine and anti-HER2 therapy, and develop new treatment strategies to overcome them.
Finally, they hope to develop a clinical test to identify patients with HER2-positive disease who can be spared chemotherapy.
Rachel Schiff, PhD
She is an internationally recognized expert in breast cancer translational research and in preclinical therapeutic models, especially concerning endocrine, HER2, and additional targeted therapies. Schiff's research focuses on understanding key signaling pathways in breast cancer and on identifying therapeutic strategies to overcome them. Major interests include molecular aspects of estrogen receptor ER and HER2 action in breast cancer, the crosstalk between the ER signaling network and growth factor receptor and cellular kinase pathways, the role of ER co-regulators in breast cancer development and progression, mechanisms of resistance to targeted therapies, and the identification of biomarker and signatures of hormonal and anti-HER2 therapy resistance for therapeutic interventions.
Skip to main content. Rachel Schiff, PhD. Stereotactic body radiation therapy or surgery for stage I—II non-small cell lung cancer treatment? Association of epidermal growth factor receptor protein expression with histopathological and clinical parameters in carcinoma of the larynx Chittibabu Vatte, Ali M.
Rodriguez, G. Larry Maxwell, Kathleen M. Darcy, Viqar Syed. A scoring model combining serum alpha-fetoprotein and tumor size and number predicts prognosis in hepatitis B virus-related hepatocellular carcinoma patients after curative hepatectomy Bai Wei, Jing-San Chen, Sheng-Li Yang, George G. Chen, Hao He. Secondary particle production and physical properties during dose enhancement for spread-out Bragg peaks Chulhwan Hwang, Jung Hoon Kim.
Albumin-bilirubin grade as a prognostic factor of hepatocellular carcinoma after treatment with orthotopic liver transplantation Jianhua Liao, Jingting Liu, Changcan Li, Junwei Fan, Zhaowen Wang. Influences of information management path coordination with dynamic monitoring on the quality of hospital drug management Xiuxin Guo, Jiwei Huang, Caiyun Jiang, Weifeng Zheng, Zhuying Liu. Primary angiosarcoma of the small intestine metastatic to peritoneum with intestinal perforation: a case report and review of the literature Zhicheng Liu, Jinhai Yu, Zhonghang Xu, Zhiwei Dong, Jian Suo.
Letter to the Editor Postmastectomy radiation therapy in women with T1—T2 tumors and 1 to 3 positive lymph nodes: analysis of the breast international group trial—a letter to the editor Paul Ramia, Joseph Abi Jaoude, Youssef Zeidan. Yan, Li-Ke Yu.
Rachel Schiff | Researcher | BCRF
Perspectives Is there still a role for tremelimumab in the treatment of cancer? Paolo A. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer Deep Kwatra, Anand Venugopal, Shrikant Anant. Historical perspective and evolution of charged particle beam therapy Huan Giap, Bosco Giap. Gold nanoparticles in radiation research: potential applications for imaging and radiosensitization Jay F. Proton therapy for gastrointestinal cancers Ted C.
Ling, Joseph I. Kang, Jerry D. Slater, Gary Y.
DNA ligases as therapeutic targets Alan E. Tomkinson, Timothy R. Howes, Nathaniel E. Normal tissue protection for improving radiotherapy: where are the Gaps? Pataje G. Prasanna, Helen B.
Stone, Rosemary S. Wong, Jacek Capala, Eric J. Bernhard, Bhadrasain Vikram, C. Clinical relevance of liquid biopsy for cancer screening Rita Tanos, Alain R. Davis, David J. Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis Chang-Lung Lee, Jordan M. Blum, David G.
- How To Be A School Volunteer (Educating Our Children Book 6);
- Translational Research - Oncology - Clinical Care Options!
- Russian Nationalism and the Politics of Soviet Literature: The Case of Nash Souremennik, 1981-1991 (Studies in Russian & Eastern European History)?
- Introduction to 64 Bit Intel Assembly Language Programming for Linux?
- Kommos Volume IV: The Greek sanctuary (1&2).
Radiosensitization by gold nanoparticles: effective at megavoltage energies and potential role of oxidative stress Karl T. Butterworth, Stephen J. McMahon, Laura E. Taggart, Kevin M. Intestinal stem cell injury and protection during cancer therapy Jian Yu. Berbeco, G. Mike Makrigiorgos, Srinivas Sridhar. Correspondence Targeted attack: mechanisms by which ovarian cancers suppress the immune system Irina V.
Tiper, Tonya J. Editorial Focusing in on radiation induced brain injury M. Lauing, Sebastian D. Otto-Meyer, Rimas V. Lukas, Derek A. Gut microbes modulate host response to immune checkpoint inhibitor cancer immunotherapy Kebin Liu, Chunwan Lu. New light on the pancreatic cyst conundrum Nathan A. Andrew J. Scott, John C. R hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas Leland G.
Richardson, Bryan D. Choi, William T. On the subventricular zone origin of human glioblastoma Akshitkumar M. Are lung adenocarcinoma mutations shaping the immune microenvironment?
- Five Lectures on Supersymmetry (FLS).
- chapter and author info.
- Cancer division!
- Top Stories.
- You are here.
- Translational Research Fellowship: Awardees & Reports?
Philippe Rochigneux, Edward B. Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts Kristopher A.